FOR THE PERIODS ENDED DECEMBER 31, 2025 and 2024 ELECTROVAYA INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in thousands of U.S. dollars) As at December 31, 2025 and September 30, 2025 | | | As at | As at | | --- | --- | --- | --- | | | | December | September | | | Notes | 31, 2025 | 30, 2025 | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | | 22,677 | 6,358 | | Restricted cash | | 2,443 | 656 | | Trade and other receivables | Note 4 | 13,964 | 16,474 ...

Technology and Innovation - SCHMID is currently in the process of patenting the technology for embedded traces (ET), which is expected to drive significant sales growth in the high-end market, particularly in North America, with substantial sales anticipated in 2026[66] - The company is investing in new product development to expand beyond traditional offerings, but market acceptance of new products is uncertain and could impact revenues[70] - The company relies on continuous development of new, improved, and cost-effective technologies and products to maintain satisfactory margins amid market commoditization[76] - The company is currently patenting technology for embedded traces, which is a next-level technology for high-end PCBs and substrates, but the official patent process is not yet completed[183] Market and Economic Conditions - The electronics industry is highly competitive, with significant pressure from large Chinese manufacturers and the need for continuous innovation to maintain market share[59][60] - Economic, financial, and geopolitical conditions could lead to business disruptions, significantly impacting future revenue and financial health[56] - Revenue and profitability are subject to fluctuations due to economic conditions, impacting future operating results[81] - The company generated a significant percentage of its revenue from the USA, China, and Europe, with potential adverse effects from economic downturns in these regions[85] - The company is sensitive to general trends in key markets, with demand for its products impacted by macroeconomic conditions and consumer confidence[87] - Economic instability, including inflation and geopolitical issues, may lead to decreased consumer confidence and increased costs, adversely affecting the company's operations and financial objectives[103] Financial Performance and Risks - SCHMID's profitability is at risk if cost management strategies fail or if competitors develop a more advantageous cost structure[74] - The company faces risks related to supply chain disruptions, material cost increases, and geopolitical tensions, which could adversely affect operations and financial condition[65] - Any disruptions in the supply chain or significant increases in material costs could adversely affect the company's operations and financial results[84] - The company’s performance is closely tied to the financial health of its customers, which may lead to reduced purchases during economic uncertainties[86] - The company may face significant revenue decreases if key customers fail to grow their own sales, potentially leading to a material adverse effect on its business and financial condition[100] - Decreases in average selling prices of products could adversely affect profitability, necessitating improvements in production efficiency or shifts to higher margin products to maintain financial health[101] - The company is at risk of recording impairment charges on accounts receivable if it cannot collect outstanding balances, which could materially impact its financial condition[102] - The company may need to seek additional financing to support ongoing operations and product development, which could restrict its ability to introduce new products and increase vulnerability to economic downturns[127] - The company’s cash and cash equivalents, along with expected operational cash flow, are believed to be adequate for ongoing requirements, but additional financing may be necessary to compete effectively[126] Regulatory and Compliance Issues - The company is subject to substantial regulation, and any unfavorable changes could harm business operations and results[58] - The company operates in various jurisdictions, exposing it to risks from differing legal and regulatory environments, which could negatively impact its global operations[106] - The company is subject to extensive regulations, and non-compliance could result in significant fines, penalties, and reputational harm[139] - Compliance with GDPR and CCPA imposes additional obligations on the company regarding personal data handling, which can be costly and may expose the company to legal and reputational risks[146] - The company faces challenges in managing an internationally dispersed business, including compliance with varying laws and regulations, which could adversely affect its financial performance[110] Corporate Governance and Shareholder Issues - Anette Schmid and Christian Schmid jointly control 56.77% of the outstanding Ordinary Shares, which may limit shareholder protections and influence company decisions[197] - As a foreign private issuer, SCHMID is exempt from certain U.S. corporate governance requirements, which may affect investor confidence and share attractiveness[206] - The company is classified as an "emerging growth company" and intends to utilize exemptions from various reporting requirements, potentially impacting market perception[204] - The company acknowledges the importance of good corporate governance but does not comply with all provisions of the Dutch Corporate Governance Code due to conflicts with NASDAQ rules[210] - Shareholders may experience substantial dilution upon future issuances of shares due to restrictions on exercising pre-emptive rights[211] Internal Controls and Reporting - SCHMID identified two material weaknesses in internal control over financial reporting as of December 31, 2023, which persisted into 2024 despite remediation efforts[192] - The company failed to finalize its financial reporting for 2024 or publish its annual report on Form 20-F in a timely manner due to accounting and liquidity issues, receiving delinquency and delisting notices from NASDAQ[200] - The inability to maintain effective internal controls could adversely affect investor confidence and the company's operating results[190] - The company’s operational and financial systems may require improvements to support growth goals, with potential adverse effects on billing and reporting if not addressed[189] Legal and Litigation Risks - The company operates in a litigious environment, which may lead to legal actions that could materially affect its financial condition and results of operations[140] - The company may be subject to claims regarding the infringement of third-party intellectual property, which could lead to costly litigation and loss of valuable rights[179] - The company may need to defend against patent or trademark infringement claims, which could incur substantial costs and distract from core operations[186] Financing and Debt Management - The company has entered into an investment agreement to sell senior convertible notes totaling $30 million, with $15 million funded on January 21, 2026, and the second tranche contingent on a registration statement being effective by June 30, 2026[128] - The company entered into a subscription agreement with XJ Harbour to issue 12,540,539 shares at $2.15 per share to offset liabilities of approximately $26.96 million[238] - A secured term loan facility of up to €10 million was signed with Black Forest Special Situations I, with the first tranche of €2.5 million drawn down in December 2025[241] - The company issued $30 million in senior convertible notes due 2028, with a 7% annual interest rate, to be funded in two tranches[245] Operational Challenges - The company faces challenges in adapting and expanding its research and development activities, which may hinder its ability to respond to market trends and technological changes[77] - The company relies on a limited number of suppliers for raw materials, and any financial distress among these suppliers could disrupt production and increase costs[159] - The company’s information technology systems are critical for operations, and failures could lead to transaction errors and loss of sales[164] - Cybersecurity risks are increasing, necessitating additional resources to mitigate new threats and enhance information security capabilities[167] Tax and Financial Regulations - The company has incurred significant tax losses, which may be limited in usability under German tax laws following shareholder changes[222] - Future changes to tax laws, including the implementation of a Global Minimum Tax regime in Germany, could adversely affect the company's tax profile and financial results[223] - The company does not expect to be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes in the foreseeable future, but this status could change based on future operations[226]

Customer Concentration - In 2025, three customers accounted for 23%, 19%, and 12% of total revenue, indicating a reliance on a few key customers for revenue generation[40] Research and Development - Research and development expenses for 2025 were $232.4 million, representing 12.2% to 14.3% of total revenue over the past three years[53] Manufacturing Operations - Manufacturing operations in Zhongshan, China ceased in Q2 2025, with final closure activities expected to conclude in 2026[45] - The company expanded capacity in its factories in the Philippines and Mexicali, and is progressing on a new factory in Thailand[45] Workforce and Safety - The company maintains a diverse workforce of approximately 13,000 employees, with a gender distribution of 53% male and 47% female[54] - The company is committed to health and safety, providing regular training and ensuring safe working conditions[56] Financial Risks - The company has exposure to foreign currency exchange rate risk, impacting revenue and purchasing transactions[239] - The company’s only outstanding debt is Convertible Notes with a fixed interest rate of 2.5%, insulating it from interest rate fluctuations[242] Intellectual Property - The company continues to invest in intellectual property, holding numerous patents and pending applications in various regions[48] Supply Chain Risks - The company’s manufacturing requires a variety of components, with some key parts sourced from sole suppliers, highlighting supply chain risks[46]

Financial Performance - Citius Pharmaceuticals reported $3.9 million in revenue for the fiscal first quarter 2026, generated from initial sales of LYMPHIR in December 2025[1][2]. - The net loss applicable to common stockholders was $8.2 million, or $(0.38) per share, compared to a net loss of $9.8 million, or $(1.30) per share, in the prior-year period[8][15]. - Net loss for 2025 was $9,393,889, an improvement from a net loss of $10,281,246 in 2024[17]. - Stock-based compensation expense increased to $4,280,227 in 2025 from $2,524,824 in 2024[17]. - Net cash used in operating activities rose to $13,008,822 in 2025 compared to $4,725,852 in 2024[17]. Cash and Financing - Cash and cash equivalents totaled $7.7 million as of December 31, 2025, with net proceeds of approximately $20.9 million from equity financings during the quarter[8]. - Net proceeds from common stock offerings significantly increased to $20,877,925 in 2025 from $2,574,051 in 2024[17]. - Cash and cash equivalents at the end of the period reached $7,721,393 in 2025, up from $1,100,079 in 2024[17]. Research and Development - Research and development expenses decreased to $1.6 million from $2.1 million in the prior-year period, reflecting reduced clinical development activity[8]. - Citius Pharma is advancing its late-stage pipeline, which includes Mino-Lok and Halo-Lido, with ongoing engagement with the FDA[4][8]. Market Strategy and Opportunities - The company aims to expand patient access and market penetration through a technology-driven platform and anticipates growth from international market opportunities[3]. - Citius Oncology's LYMPHIR is targeted for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma, with an estimated initial market exceeding $400 million[5][9]. - The company has initiated agreements for international patient access to LYMPHIR through Named Patient Programs in Europe and the Middle East[8]. - Citius Oncology has deployed an AI-enabled commercial platform to enhance physician engagement and market penetration in a concentrated prescriber base[8]. Operational Changes - General and administrative expenses increased to $5.7 million compared to $5.4 million in the prior-year period[8]. - License fee payments in investing activities amounted to $4,400,000 in 2025, with no such payments in 2024[17]. - Changes in accounts receivable resulted in a decrease of $4,049,111 in 2025, with no allowances reported in 2024[17]. - Inventory decreased by $352,649 in 2025, a significant improvement compared to a decrease of $6,112,603 in 2024[17]. - Accrued expenses decreased by $5,722,097 in 2025, contrasting with an increase of $6,225,151 in 2024[17]. - Interest paid in 2025 was $14,460, with no interest paid reported in 2024[17].

Financial Performance - Citius Oncology reported $3.9 million in revenue for the fiscal first quarter ended December 31, 2025, marking its first reported revenue following the launch of LYMPHIR[1][7]. - The net loss for the quarter was $5.5 million, or $(0.06) per share, compared to a net loss of $6.7 million, or $(0.09) per share, for the prior-year period[7][14]. - The net loss for 2025 was $5,534,069, an improvement from a net loss of $6,659,205 in 2024[16]. - Stock-based compensation expense increased to $3,956,050 in 2025 from $1,808,478 in 2024[16]. - Net cash used in operating activities was $(7,354,946) for 2025, with significant changes in accounts receivable and inventory[16]. - License payments in investing activities amounted to $(4,400,000) in 2025[16]. - Net proceeds from the issuance of common stock were $15,125,489, contributing positively to financing activities[16]. - The net change in cash and cash equivalents for 2025 was an increase of $3,370,543[16]. - Cash and cash equivalents at the end of the period reached $7,295,451, up from $3,924,908 at the beginning of the period[16]. - Interest paid during the period was $14,460[16]. Operational Developments - The company established a nationwide specialty distribution infrastructure to ensure immediate product availability and support rapid physician adoption of LYMPHIR[4][7]. - Citius Oncology is advancing an international access strategy through regional distribution partners and Named Patient Programs in key European and Middle Eastern markets[7][4]. - The company is focused on expanding its field presence to support a concentrated prescriber base in the rare cancer setting, utilizing an AI-enabled commercial platform[2][7]. Market Opportunity - The initial market for LYMPHIR is estimated to exceed $400 million and is growing, indicating a significant opportunity in an underserved market[6][7]. Cost Management - Research and development expenses decreased to $1.0 million from $1.3 million in the prior-year period, reflecting reduced clinical development activity[7][14]. - General and administrative expenses were $2.9 million, down from $3.3 million in the prior-year period[7][14]. Strategic Focus - Citius Oncology is evaluating strategic opportunities to enhance long-term shareholder value while maintaining capital management[3][7].

Financial Performance - Citius Oncology reported $3.9 million in revenue for the fiscal first quarter 2026, marking its first reported revenue following the launch of LYMPHIR in December 2025[1][7]. - The net loss for the quarter was $5.5 million, or $(0.06) per share, compared to a net loss of $6.7 million, or $(0.09) per share, for the prior-year period[7][14]. - The net loss for 2025 was $5,534,069, an improvement from a net loss of $6,659,205 in 2024[16]. - Stock-based compensation expense increased to $3,956,050 in 2025 from $1,808,478 in 2024[16]. - Net cash used in operating activities was $(7,354,946) for 2025, with significant changes in accounts receivable and inventory[16]. - License payments for investing activities amounted to $(4,400,000) in 2025[16]. - Net proceeds from the issuance of common stock were $15,125,489, contributing positively to financing activities[16]. - The net change in cash and cash equivalents for 2025 was an increase of $3,370,543[16]. - Cash and cash equivalents at the end of the period reached $7,295,451, up from $3,924,908 at the beginning[16]. - Interest paid during the period was $14,460[16]. Expenses - Research and development expenses decreased to $1.0 million from $1.3 million in the prior-year period, reflecting reduced clinical development activity[7][14]. - General and administrative expenses were $2.9 million, down from $3.3 million in the prior-year period[7][14]. Market Opportunity - The initial market for LYMPHIR is estimated to exceed $400 million and is growing, indicating a significant opportunity in an underserved market[6][7]. - Citius Oncology is advancing an international access strategy through regional distribution partners and Named Patient Programs in key European and Middle Eastern markets[7][4]. - The company is focused on expanding its field presence to support a concentrated prescriber base in the rare cancer setting, utilizing an AI-enabled commercial platform[2][7]. Strategic Focus - Citius Oncology is evaluating strategic opportunities to enhance long-term shareholder value while maintaining capital management[3][7]. - The company established a nationwide specialty distribution infrastructure to ensure immediate product availability and support rapid physician adoption of LYMPHIR[4][7].

Product Development and Innovation - Astrotech's TRACER 1000™ is the world's first mass spectrometry-based explosives trace detector certified by ECAC and approved by TSA for air cargo, currently deployed in approximately 35 locations across 16 countries[92][93]. - The TRACER 1000 has been approved for the Air Cargo Security Technology List, advancing it to Stage II testing with TSA, which includes field trials to ensure readiness for certification[94]. - AgLAB's 1000-D2™ mass spectrometer has demonstrated the ability to improve THC and CBD oil yields by approximately 15% to 30% during distillation processes[106]. - Pro-Control has introduced the Pro-Control Maximum Value Processing and Pro-Control 1000-D2™ mass spectrometer to enhance efficiency in industrial chemical distillation processes[112]. - EN-SCAN, a new subsidiary, is focused on environmental testing instruments for real-time air, water, and soil analysis, utilizing proprietary ATi Gas Chromatograph and AMS Technology[113]. - The TRACER 1000 Narcotic Trace Detector was launched to address the global drug crisis by screening for synthetic opiates and novel psychoactive substances[98]. Market Opportunities - In fiscal year 2023, the U.S. federal government budgeted over 6,000 ETD units for checkpoint and baggage screening, indicating a significant market opportunity for the TRACER 1000[95]. - AgLAB is targeting the rapidly growing CBD and hemp market, which is expected to expand due to increasing acceptance of medicinal cannabis and regulatory changes[103][104]. - Astrotech has secured a $429,000 purchase order for TRACER 1000 ETDs from a TSA-approved contractor, marking its first TSA-approved sale[99]. Financial Performance - Total revenue for the three months ended December 31, 2025, decreased by $113 thousand to $148 thousand compared to $261 thousand in the same period in 2024, primarily due to lower instrument and grant revenue[116]. - Gross profit for the three months ended December 31, 2025, was $8 thousand, resulting in a gross margin of 5%, a decline of 54% from 59% in the same period in 2024[117]. - Operating expenses decreased by $567 thousand, or 12.7%, during the three months ended December 31, 2025, compared to the same period in 2024[118]. - Research and development expenses decreased by $605 thousand, or 24.8%, during the three months ended December 31, 2025, compared to the same period in 2024[119]. - Total revenue for the six months ended December 31, 2025, increased by $150 thousand to $445 thousand compared to $295 thousand in the same period in 2024, driven by a $220 thousand increase in grant revenue[120]. - Gross profit for the six months ended December 31, 2025, was $196 thousand, with a gross margin of 44%, down from 56% in the same period in 2024[121]. - Cash used in operating activities increased by approximately $749 thousand to $7,479 thousand for the six months ended December 31, 2025, compared to $6,730 thousand in 2024[124]. - Cash provided by investing activities increased by approximately $8 million, primarily from $8.4 million of proceeds from short investments[127]. - As of December 31, 2025, cash and cash equivalents were approximately $3.1 million, down from $3.2 million as of December 30, 2024[125]. - The Company expects its effective tax rate for the full fiscal year 2026 to remain at 0% due to cumulative losses and expected future losses[132]. Research and Future Directions - The company is exploring advancements from BreathTech's research to apply in other business units, although commercialization in breath analysis may require significant investment and time[110].

Exhibit 99.1 Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results AUSTIN, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the "Company" or "Astrotech") reported its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025. About Astrotech Corporation Astrotech Corporation (Nasdaq: ASTC) is an instrumentation company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiar ...

Revenue Performance - Net revenue for the three months ended December 31, 2025, was $6.7 million, an increase from $6.2 million in the same period last year, primarily due to higher prices[7] - Net revenue for the six months ended December 31, 2025, was $11.9 million, down from $12.8 million in the same period last year, attributed to strategic growing decisions[8] - Revenue for the three months ended December 31, 2025, was $6,739,000, an increase of 8.8% compared to $6,192,000 for the same period in 2024[25] Profitability - Gross profit for the three months ended December 31, 2025, was $0.5 million, or 7.2% of sales, compared to a gross loss of $0.6 million, or (9.4)% of sales, in the prior year[9] - Gross profit for the six months ended December 31, 2025, was $0.4 million, or 3.6% of sales, compared to $0.9 million, or 6.7% of sales, in the prior year[10] - Gross profit for the six months ended December 31, 2025, was $424,000, down from $858,000 in 2024, indicating a decline of 50.6%[25] Operating Performance - Operating loss for the three months ended December 31, 2025, was $2.3 million, an improvement from an operating loss of $3.9 million in the same period last year[11] - Operating loss for the three months ended December 31, 2025, was $(2,289,000), an improvement from $(3,887,000) in 2024, representing a 41.0% reduction in losses[25] Net Loss - Net loss from continuing operations for the three months ended December 31, 2025, was $2.7 million, compared to a loss of $3.4 million in the prior year[13] - Net loss attributable to Bloomia Holdings, Inc. for the six months ended December 31, 2025, was $(5,130,000), compared to $(4,065,000) in 2024, reflecting an increase in losses of 26.2%[25] EBITDA - EBITDA for the three months ended December 31, 2025, was a loss of $1.4 million, an improvement from a loss of $2.7 million in the same period last year[17] - EBITDA for the three months ended December 31, 2025, was $(1,377,000), an improvement from $(2,711,000) in 2024, indicating a 49.1% reduction in negative EBITDA[30] Cash Flow and Liquidity - Cash used in operations for the six months ended December 31, 2025, was $11.4 million, compared to $9.0 million in the same period last year[6] - As of December 31, 2025, cash and cash equivalents totaled $1.2 million, an increase from $0.9 million as of June 30, 2025[19] - Cash and cash equivalents increased to $1,209,000 as of December 31, 2025, compared to $906,000 as of June 30, 2025, representing a growth of 33.4%[27] - Working capital improved significantly to $9,613,000 as of December 31, 2025, from $1,089,000 as of June 30, 2025[27] Debt and Assets - Total assets as of December 31, 2025, were $105,607,000, up from $97,924,000 as of June 30, 2025, showing a growth of 7.0%[27] - Total debt increased to $47,021,000 as of December 31, 2025, from $34,083,000 as of June 30, 2025, marking a rise of 38.0%[27] Future Plans - The Company plans to commence a Rights Offering, with the updated expiration date set for March 27, 2026[20] Earnings Per Share - The company reported a net loss per share of $(1.29) for the three months ended December 31, 2025, compared to $(1.67) in 2024, reflecting a 22.8% improvement[25]

Exhibit 99.1 Contact: Bloomia Holdings, Inc. Biz McShane, CFO (763) 392-6200 MINNEAPOLIS, MN – February 13, 2026 – Bloomia Holdings, Inc. (Nasdaq: TULP) ("Bloomia Holdings" or the "Company") today announced its financial results for the second fiscal quarter ended December 31, 2025. Overview Three Months Ended December 31, 2025 Six Months Ended December 31, 2025 Bloomia Holding's Chairman and Co-Chief Executive Officer, Mark Jundt, commented, "This quarter, along with the quarter preceding it, represents an ...